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Abstract
Depression is a ubiquitous disorder in childbearing women with up to 10% of women experiencing depression in
pregnancy. Postpartum depression occurs in 12]16% of pregnancies making it a common complication. Moreover,
these illnesses are frequently underdiagnosed in obstetric settings, and a recent report of the Surgeon General’s
Office confirms that many women do not access services, or receive treatment of inadequate intensity or duration.
This paper provides current treatment guidelines to aid in appropriate diagnosis and treatment of depression in
pregnancy and postpartum. Review of current literature on psychotropic medication use in pregnancy is also
provided. Q 2001 International Federation of Gynecology and Obstetrics. All rights reserved.
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1. Introduction
Depression is among the most common of
health disorders in women. There are five key
factors that are important to further characterize
Ž .predictors of Major Depressive Disorder MDD
during pregnancy in order to develop more effec-
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tive strategies for treatment and prevention. First,
almost one woman in four will experience depres-
w xsion at some point in her life 1 . Second, depres-
sive episodes present most often during the child-
bearing years, and almost 10% of women will
w xexperience depression during pregnancy 2 . Third,
MDD is now recognized as a recurrent disorder,
with risks of relapse increasing for those with
prior episodes following antidepressant discontin-
uation. Fourth, it is commonplace for physicians
to withdraw antidepressant medications at the
time of conception for women receiving treat-
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ment for depression. Fifth, there is little informa-
tion available about specific risk factors for re-
lapse during pregnancy, or strategies for prevent-
ing episodes. It is critical for clinicians treating
childbearing women to have information available
to guide them in treatment decisions as they
negotiate the delicate balance between use of
psychotropic medication during pregnancy vs. the
risks of undertreating the woman’s depressive ill-
ness and risking relapse. The purpose of this
paper is to review the available data on the risks
and sequelae of using various psychotropic medi-
cations during pregnancy and lactation, and to
provide guidelines for the treatment of major
mood disorders through pregnancy and postpar-
tum. These guidelines will emphasize pharmaco-
logic, psychotherapeutic, and psychosocial man-
agement strategies.
1.1. Background
Although there have been advances in psy-
chopharmacologic treatment for depression, a re-
cent report of the United States Surgeon Gen-
eral’s Office confirms that many women do not
seek treatment. Many who do seek treatment for
depression do so in the primary care setting where
50% go unrecognized and many more are under-
w xtreated 3 . At the University of Michigan Health
System, pilot data suggests that a diagnosis of
depression is made in only 0.8% of childbearing
w xwomen 4 , however, national data suggests
10]20% prevalence of the disorder in medicalr
w xsurgical settings 5 . Of those who are diagnosed,
most receive inadequate treatments. In addition,
medical adherence is extremely problematic; half
of antidepressants prescribed are not filled after
w xthe first month 6 . The under-detection and un-
der-treatment of depression in women of child-
bearing age leads to substantial maternal and
infant morbidity, and medical costs. Psychiatric
illness has adverse consequences in pregnancy
including inadequate nutrition, poor compliance
with prenatal care, poor pregnancy outcomes,
substance abuse, and dangerous risk-taking be-
w xhavior 7 . The more dramatic outcomes such as
risk taking, fetal abuse, or maternal suicide may
be the disastrous consequences of untreated
w xdepression in pregnancy 8 . In women with
bipolar illness, the risk of postpartum relapse is
well established and estimated between 30 and
50% particularly when mood stabilizers are dis-
w xcontinued 9 .
Due to the prevalence of psychiatric disorders
in childbearing women, many women are using
psychotropic medications at the time of concep-
tion. As all psychoactive medications cross the
placental barrier, the woman’s health and disease
management must be balanced against the risk of
infant exposure during pregnancy. Many times
the risk of medication is outweighed by the sub-
stantial morbidity of the undertreated illness.
2. Research on adverse effects of psychotropic
medications in pregnancy
Psychotropic medications potentially can have
Ž .three types of adverse effects on the fetus: 1
teratogenic effects increase risk of congenital
malformation usually during the first trimester;
Ž .2 neonatal toxicity and withdrawal syndromes
are usually related to ongoing third trimester
Ž .exposure; 3 behavioral effects are more difficult
to characterize and are manifest by later behav-
ioral and developmental difficulties in the child.
The FDA has assigned risk categories B, C, D,
and X to different psychotropic medications. Cat-
egory A indicates no risk. The risk categories are
useful even though estimates of the teratogenic
effects of various psychotropic medications are
imprecise. Bupropion, clozapine, and buspirone
have received the B designation, which indicates
an absence of human risk with the caveat of
Žlimited data. SSRIs fluoxetine, sertraline, paroxe-
.tine , desipramine, venlafaxine, mirtazapine, nefa-
zodone, clonazepam, and most conventional and
atypical antipsychotics have received the C desig-
nation. This denotes that human risk cannot be
entirely eliminated because of inadequate human
clinical trials and either no animal studies or, in
some, evidence of risk in animals. The D designa-
tion has been assigned to lithium, carbamazepine,
sodium valproate, most tricyclic antidepressants,
Žand other benzodiazepines other than clo-
.nazepam , indicating evidence of fetal risk but not
( )S.M. Marcus et al. r International Journal of Gynecology & Obstetrics 72 2001 61]70 63
an across the board contraindication during preg-
nancy. Benzodiazepines, including triazolam,
temazepam, flurazepam, and quazepam have re-
Ž .ceived the X completely contraindicated desig-
nation.
3. Antidepressant and mood stabilizing agents
There are significant methodological issues in
the study of antidepressant medications in preg-
nancy. Factors including the use of other medica-
tions, the impact of other comorbid illnesses and
use of alcohol and nicotine, genetic factors, ma-
ternal age, and time of gestation can confound
w xthe results of studies in this area 10 . Table 1
includes the teratogenicity, neonatal toxicity, and
behavioral risks associated with antidepressant
and mood stabilizing agents during pregnancy and
lactation. This section briefly summarizes the most
salient studies for each type of agent.
3.1. Selecti¤e serotonin reuptake inhibitors
3.1.1. Pregnancy
ŽRecent research on the use of SSRIs fluoxe-
.tine, sertraline, paroxetine, fluvoxamine suggests
that they are relatively safe for both the mother
and fetus during pregnancy. Studies with fluvox-
amine, paroxetine and sertraline have failed to
w xshow an increased risk of fetal anomalies 11,12 .
There have been no maternal reports of adverse
w xsequelae in the infants exposed to sertraline 13 .
Moreover, longer term studies assessing infant
development reveal that infants exposed to a vari-
ety of tricyclic agents as well as fluoxetine were
developmentally normal and similar to sibling
controls on measures of IQ and learning at the
w xage of 5 years 14 . In another European study, no
increase in congenital abnormalities was found in
the perinatal period in 969 infants whose mothers
w xused SSRIs andror tricyclic antidepressants 15 .
The study was unique in that it included 375
infants exposed to citalopram, a newly approved
SSRI in the United States. These findings did not
support two adverse reaction reports linking
citalopram during early pregnancy with optic
nerve hypoplasia and septum pellucidum defects.
Not all studies have supported the safety of the
w xSSRIs in pregnancy and one group 16 concluded
from a prospective cohort study that the infants
of women who take fluoxetine in the first trimester
are at increased risk for minor anomalies, such as
larger for their gestational age with 55% falling
into the 90th percentile and above for birthweight
indicating a teratogenic effect. They also reported
that those exposed during the third trimester are
at increased risk for premature delivery, poor
neonatal adaptation, cyanosis on feeding, and jit-
teriness. The findings of this study have been
criticized for confounding factors of severity of
depressive illness in the mother and increased
w xmaternal age 17 .
3.1.2. Lactation
Fluoxetine and sertraline are secreted in breast
milk and there is one report of infant irritability
with exposure to fluoxetine through lactation,
though no reports of neonatal difficulties in lac-
w xtating infants who’s mothers used sertraline 12 .
Paroxetine was not found in measurable quanti-
ties in breast milk, and there were not reports of
infant difficulties when this agent was used.
3.1.3. General information
SSRIs are excellent first line agents and can
also be used with panic disorder or obsessive
compulsive disorder. Potential side effects fluox-
etine can include agitation, insomnia, gastroin-
testinal distress such as nausea or diarrhea, facial
tension or headaches, sexual side effects, or weight
gain.
3.2. Tricyclic antidepressants
3.2.1. Pregnancy
There are many studies exploring the risk of
fetal exposure to the tricyclic agents during preg-
nancy. A comprehensive review of the literature
from 1966 to 1995 did not reveal an association
between fetal exposure to tricyclic antidepres-
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sants and rates or clustering of congenital malfor-
w xmation in 414 cases of first trimester exposure 9 .
3.2.2. Lactation
Long-term follow-up studies on developmental
outcomes of infants exposed to tricyclics through
lactation are limited. These agents are secreted in
breast milk, with a serum to milk ratio approxi-
mately equal to 1. Levels in infant serum are
variable and sometimes undetectable. Despite a
limited database, most reviews support the use of
Žsecondary amine tricyclics nortriptyline and de-
.sipramine as first line agents for treatment of
w xdepression in nursing women 12 .
3.2.3. General information
Tricyclics are good agents for patients with
proven response but they have more side effects
than SSRIs. Side effects include dry mouth,
blurred vision, constipation, dizziness, cardiac
symptoms, sedation or agitation, and weight gain.
These agents can be lethal in an overdose.
3.3. Other antidepressant agents
Monoamine oxidase inhibitors have been asso-
ciated with growth retardation, congenital
anomalies and fetal death in animal and human
studies and are contraindicated in pregnancy. Ad-
ditionally, there are no published controlled clini-
cal trials involving bupropion, venlafaxine, trazo-
done, or mirtazapine during pregnancy or lac-
tation. Animal studies with bupropion have
revealed no evidence of impaired fertility or fetal
harm and retrospective analysis in the bupropion
pregnancy registry did not show increased fetal
w xanomalies 18 .
3.4. Alternati¤e therapies and the nutraceuticals
European double blind placebo controlled
Žstudies involving St John’s Wort Hypericum per-
.foratum have demonstrated efficacy in treating
mild-moderate depression but the potency of the
psychoactive substance and contaminants in the
various preparations confound these studies.
More research is needed in this area. Because
some women self-medicate with herbal remedies,
assuming them to be ‘natural’ and fail to consider
potential toxicity in pregnancy or lactation, it is
important for clinicians to inquire about herbal
remedies when obtaining clinical histories in
childbearing women.
3.5. Benzodiazepines
The early literature on benzodiazepines sug-
gests that they contribute to cleft palate during
first trimester exposure though the degree of risk
is difficult to determine. The risk of cleft palate in
the general population is approximately 0.064%.
In women using benzodiazepines during the first
trimester, the risk appears to be increased, but
still less than 1% in infants of women who are
w xexposed 9 . There is evidence for adverse neona-
tal syndromes associated with consistent late third
trimester exposure to benzodiazepines, including
‘floppy infant syndrome’ with hypotonia, lethargy,
and poor temperature regulation.
3.6. Mood stabilizers
Lithium has been well studied in pregnancy
and general cardiac anomalies occur in approxi-
mately 7% of bipolar women taking lithium. The
degree of risk of the most common cardiac
anomaly, Epstein’s Anomaly, is estimated at 0.1%
or 10]20 times the rate in the general population.
This is much lower than initial estimates from the
w xInternational Register of Lithium Babies 19 .
Lithium is associated with neonatal morbidity and
toxicity in the neonate and may result from non-
toxic maternal levels. Clinical manifestations in-
clude hypotonia, hypothyroidism, cyanosis,
lethargy, poor sucking, and abnormal reflexes.
Prenatal exposure to valproic acid has been
associated with a 1]5% risk of neural tube de-
fects. The incidence of neural tube anomalies in
carbamazepine exposed children is 0.5% and other
anomalies such as hypoplastic nails and craniofa-
w xcial anomalies have also been identified 9 . Risk
may be increased with the use of multiple anti-
convulsant drugs or higher maternal plasma lev-
els. The data on behavioral teratogenicity related
to anticonvulsant exposure is difficult to interpret
because the results are complicated by factors
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such as parental IQ, impact of seizure disorders
in pregnancy, maternal blood levels of anticonvul-
w xsants, and timing of exposure 9 . A prospective
controlled trial demonstrated no adverse neu-
robehavioral outcome in exposed children as indi-
w xcated by IQ and language development 20 . Car-
bamazepine is metabolized more rapidly neona-
tally than lithium and may be a safer agent for
nursing mothers.
4. Management of depression in pregnancy
Depression that is left untreated or not properly
treated has been shown to negatively impact the
health and overall functioning of women during
pregnancy and in the postpartum. The following
treatment guidelines are provided to assist with
proper treatment in this population.
4.1. Step 1 } making a diagnosis
Establishing a diagnosis of depression is a criti-
cal first step in its treatment. Frequent tearful-
ness, irritability or complaints of insomnia are
clues that depression screening is necessary.
Patients who present with features of depression
for a period of two weeks or greater and who
have impaired psychosocial functioning warrant a
Ždiagnosis of major depressive disorder see Table
.2 . Many women are not forthcoming about their
symptoms and may present with somatic manifes-
tations of their illness. Sleep problems, headache,
fatigue, gastrointestinal distress, or anxiety are
common complaints. A comprehensive evaluation
should include thyroid screening, as well as as-
sessment for alcohol abuse. Many women who are
depressed may use alcohol to self-medicate their
symptoms. Other medications including proges-
terone containing compounds, cardiac medica-
tions, steroids, antihistamines, analgesics, and
anticholingergics may induce depressive symp-
toms.
4.2. Step 2 } determine se¤erity of illnessrperiod
of interepisode wellbeing
Many women prefer to remain medication free
during their pregnancy if their symptoms are not
severe. Patients with only mild impairment of
mood, in whom sleep and appetite are unim-
paired, and who have reasonable daytime
functioning and no suicidal ideation would be
candidates for non-pharmacologic management
strategies. Likewise, childbearing women taking
antidepressant agents at the time of conception
may discontinue them, assuming they are asymp-
tomatic, have a long period of inter-episode well-
Table 2
w xDiagnostic and Statistical Manual of Mental Disorders } IV Diagnostic 21 criteria for Major Depressive Episode
[Fi¤e or more of the following symptoms that ha¤e been present for the same 2-week period or longer at least one
( ) ( ) ]symptoms is either: 1 depressed mood or 2 loss of interest or pleasure :
Depressed mood most of the day nearly every day
Diminished interest or pleasure in almost all activities most of the day nearly every day
Ž .Significant weight loss more than 5% body wt. when not dieting or significant change in appetite nearly every day
Insomnia or hypersomnia nearly every day
Psychomotor agitation or retardation nearly every day
Fatigue or loss of energy nearly every day
Feelings of worthlessness or excessive or inappropriate guilt nearly every day
Diminished ability to think or concentrate or indecisiveness nearly every day
Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt or specific plan
for committing suicide
The symptoms cause clinically significant distress or impairment in social, occupational or other
important areas of functioning
The symptoms are not due to the direct physiological effects of a substance or medical condition
The symptoms are not better accounted for by bereavement
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being, and a history of mild illness. Prepregnancy
planning is important in this population so that
decisions can be made regarding pharmacother-
apy. Medications should be weaned, as precipi-
tous discontinuation may predispose to relapse.
Women who are medication free should be care-
fully followed for recurrence or exacerbation of
symptoms during their antenatal visits.
4.3. Step 3 } initiating pre¤ention strategies for
women with mild illness
Many therapeutic prevention strategies may be
employed to prevent the exacerbation of minor
symptoms, including a healthy diet free of al-
cohol, nicotine, and caffeine. Emphasizing proper
sleep hygiene, stress management, and exercise
are helpful measures. Mobilizing support systems
may also be helpful in preventing relapse in
women who are single or geographically distant
from extended family. Individual or conjoint
treatment is a very helpful adjunctive strategy
especially when psychosocial stressors exist. Re-
ferral for cognitive behavioral therapy, or inter-
personal therapy also reduces relapse risk in vul-
nerable populations of women with past history of
major depression. Close monitoring during ante-
natal checks is important, and clinicians should
proceed with pharmacotherapy, if symptoms be-
come more severe.
4.4. Step 4 } pharmacological treatments of major
depression
The psychosocial management strategies de-
scribed above should always be used as adjunctive
strategies even in women with more severe ill-
ness. Women who have moderate to severe illness
impeding their ability to care for themselves
nutritionally or medically, or who are predisposed
to significant anxiety, insomnia, risk-taking, or
suicidal thinking, are candidates for pharma-
cotherapy in pregnancy. Women who have had
severe episodes of depression that have recurred
with medication discontinuation should also con-
tinue pharmacotherapy. Consulting psychiatrists
may be helpful in reassuring women about medi-
cations choices and providing or referring for
adjunctive services. Full discussion of available
research, treatment options, risks of undertreat-
ing depression, and benefits of medication are
paramount in pregnancy. Medications should be
used at the lowest dose necessary to improve
symptoms, however, increased metabolism in
pregnancy may necessitate higher doses relative
to pre-pregnancy.
As stated, the selective serotonin reuptake in-
hibitors and the secondary amine tricyclic antide-
pressants are preferred agents in pregnancy and
appear safe even in the first trimester. Personal
or family history of response to a given agent
frequently guides the first choice. Additionally,
many women prefer to avoid the side effects of
the tricyclic agents. The selective serotonin reup-
take inhibitor fluoxetine has been best studied in
pregnancy. Preliminary studies on sertraline,
paroxetine, and citalopram are similarly encour-
aging without evidence of teratogenicity. These
should be considered for women who have previ-
ously had good outcomes. The tricyclic antide-
pressants nortriptyline and desipramine are good
candidates for use in pregnancy because they
tend to cause less orthostatic hypotension, dry
mouth and constipation. They should be con-
sidered in women who have failed trials with the
SSRIs or with previous good response. Caution
should be employed in women with severe suici-
dal ideation because of the risk of cardiac ar-
rhythmias when tricyclics are used in overdose.
Weaning tricylic antidepressants prior to the time
of delivery is contraindicated because fetal with-
drawal syndromes pose greater risk to the fetus
than extrauterine withdrawal and places the
woman at risk for relapse. MAOIs are contraindi-
cated in pregnancy. There is limited information
about pregnancy risks of bupropion, nefazodone,
and venlafaxine. Generally patients should be
seen by a physician or contacted by a member of
the nursing staff every few weeks until symptoms
begin to remit. Medications should be continued
for 6 months following delivery to prevent exac-
cerbation during the postpartum.
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4.5. Step 5 } adjuncti¤e strategies for refractory
illness
Some women do not respond well to the first
agent chosen. If a patient experiences partial
symptom relief, generally increasing the dose of
the primary agent is indicated. Choosing another
agent within the SSRI or tricyclic class is indi-
cated for patients who are entirely unresponsive
to the first agent within the first trimester. Elec-
troconvulsive therapy should be considered for
severe debilitating depression with nutritional
compromise. Referral for psychiatric co-manage-
ment is advised in this circumstance. Disclosure
of available research about use of these agents,
and risk of undertreatment of illness is critical in
preparing a woman and her family for use of the
medications.
4.6. Step 6 } continuing or initiating treatment for
depression during the postpartum
Women who are at risk for postpartum depres-
sion include those with mood symptoms during
pregnancy, marital discord, and family or perso-
nal history of depression. For women at risk but
who remain asymptomatic, or those with mild
symptoms of postpartum depression, non-
Žpharmacologic prevention strategies diet, exer-
.cise, stress management may be employed ini-
tially. As in pregnancy, thyroid function testing
and assessment of alcohol intake are important
screens. Maintaining circadian rhythm is very im-
portant during the postpartum. Whenever possi-
ble, women at risk should arrange for doula ser-
vices, or family assistance with night-time feed-
ings. Women who have had prior episodes of
severe postpartum depression should consider
reintroduction of their antidepressant in the third
trimester. This strategy ensures that they will
have adequate blood levels upon delivery. For
women with prior histories of mild illness, and
those experiencing first episodes of postpartum
depression, medications should begin after deliv-
ery. Many women choose to lactate and can be
encouraged to do so, though for the severely
depressed this may not be possible. Generally, the
SSRIs as well as the tricyclic agents appear to be
quite effective in postpartum depression and may
be used during lactation. Benzodiazepines are
relatively contraindicated in lactating women as
they act as CNS depressants in the neonate and
may cause kernicterus when used within the first
week of life. Benadryl is a reasonable agent to
consider for sleep, trazodone has been used clini-
cally but is not well studied.
5. Management of bipolar illness in pregnancy
and postpartum
5.1. Step 1 } establishing a diagnosis
Most patients who have bipolar illness will have
been seen previously by a psychiatrist, and new
onset bipolar illness should be referred for de-
finitive diagnosis.
5.2. Step 2 } determining se¤erity and course of
illness
When women have had long periods of quies-
cence in their illness prior to conception, a medi-
cation wean should be considered during the first
trimester. Medications should be tapered gradu-
ally, to avoid relapse and should be done in
consultation with psychiatric services. For women
with prominent mood symptoms psychopharmaco-
logic strategies are required.
5.3. Step 3 } initiating pharmacotherapy
In women with significant mood liability, in-
somnia, nutritional compromise or risk taking be-
havior, mood stabilizers should be used. They are
relatively contraindicated in the first trimester,
but symptom severity sometimes dictates contin-
ued use during this period. Discussion of risks of
medications, including cardiac and neural tube
defects, as well as risks of untreated illness, is
paramount to encourage compliance with medica-
tions. Relapses of bipolar illness should be treated
aggressively with mood stabilizers when clinically
indicated. Exposure to the anticonvulsants in the
first trimester is associated with an increased risk
of neural tube defects. Therefore, lithium is pre-
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ferred in the first trimester because its risk for
Ž .Ebstein’s anomaly is relatively remote 0.1% . Ul-
trasound with full fetal survey should be obtained
at 16]18 weeks to assess for congenital anomalies
when any of the mood stabilizers are used. Folate
Ž .4 mgrday is also recommended for all women 4
weeks prior to conception and throughout the
first trimester when the anticonvulsants are used,
pediatric teams should be arranged at the time of
delivery to optimize neonatal outcomes. Lithium
should be prescribed in multiple daily dosings to
avoid exposing the infant to large variations in
blood levels with close monitoring in the third
trimester and postpartum due to variations in
blood levels. It should generally be continued for
6]12 months following delivery to avoid postpar-
tum exacerbation of illness.
5.4. Step 4 } treatment resistance and treatment of
psychosis
ECT is indicated if rapid reconstitution is es-
sential. Psychosis with delusions and command
hallucinations present a psychiatric emergency,
and it is this clinical situation which may be a
predisposing factor in the disastrous consequence
of suicide or fetal abuse. Hospitalization and the
addition of neuroleptics are always required if the
woman and her fetus are at risk.
5.5. Step 5 } treatment of bipolar illness in
postpartum
All patients who have bipolar illness need to be
monitored quite closely during the postpartum
period. For patients who have had previous exac-
erbations of bipolar illness during the puer-
perium, it is prudent to re-institute the mood
stablizer at the time of delivery, as this signifi-
cantly reduces the risk of relapse from 50 to 70%
to a more modest 10]20%. Lithium levels should
be closely monitored shortly after delivery be-
cause of the risk of toxicity. Breastfeeding is
relatively contraindicated with use of lithium due
to its concentration within the neonate. Carba-
mazepine, with its rapid metabolism is slightly
preferred for nursing mothers, although these
infants should be very closely monitored. Any
evidence of suicidal thinking, hallucinations,
voiced concern about harming the infant or disor-
ganized thinking about the infant’s health should
be viewed as psychiatric emergencies. Hospital-
ization, aggressive pharmacotherapy and ECT are
treatments of choice.
6. Referral considerations
Many obstetricians are quite comfortable
managing uncomplicated major depression. Pri-
mary care is the ‘de facto’ mental health system
in the country. Patients who respond well to SS-
RIs and tricyclic agents can usually be managed
in primary care. Such patients should be moni-
tored by physicians and nursing staff every few
Žweeks until their acute phase symptoms sleep,
.appetite, mood have resolved. Compliance with
medication is also important to monitor as over
50% of patients discontinue medication within
the first month. Refractory illness or complex
bipolar disorder may require psychiatric consulta-
tion. In women who have active suicidality, a
history of psychosis, emerging symptoms of disor-
ganized thinking, or hallucinations or delusions,
referral for psychiatric management is recom-
mended and hospitalization is often required.
ŽOther co-morbid problems eating disorders, sub-
.stance abuse, panic disorder with agoraphobia or
persistent psychosocial problems also frequently
require more formalized mental health treat-
ments.
7. Conclusions
All psychotropic agents freely cross the placen-
tal barrier and expose the fetus to those medica-
tions; therefore, the risks of untreated psychiatric
illness must always be balanced with the risk of
fetal or infant exposure. While some mood
stabilizers may increase the absolute risk for ter-
atogenicity, that risk should be considered in the
entire context of the woman’s illness and the
adverse consequences of untreated depression.
Further study is essential to elucidate risk fac-
tors that predispose women to relapse with dis-
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continuation of medication. Additional informa-
tion and long-term studies examining behavioral
effects in children who are exposed to these agents
in pregnancy and lactation are also essential as
well as studies on newer agents and nutraceuti-
cals.
The need for treatment of this serious,
sometimes life-threatening, illness during the pre-
and postpartum periods has been under-recog-
nized with potentially serious consequences for
women and their children. While more research
is necessary to determine the fetal safety of newer
antidepressant agents, much of the evidence to
date indicates that there is no increased risk of
teratogenicity or fetal anomalies with the use of
antidepressant agents during pregnancy. New re-
search and treatment guidelines will serve to in-
form the medical community about the appropri-
ateness of treatment as well as state-of-the-art
techniques and medications to serve this
widespread and vulnerable patient population.
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